Correction to: Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis.

Emery, Paul; Tanaka, Yoshiya; Cardillo, Tracy; Schlichting, Douglas; Rooney, Terence; Beattie, Scott; Helt, Cameron; Smolen, Josef S

Emery, Paul; Tanaka, Yoshiya; Cardillo, Tracy; Schlichting, Douglas; Rooney, Terence; Beattie, Scott; Helt, Cameron; Smolen, Josef S.

Afiliación

Emery P; Leeds Muscoloskeletal Biomedical Research Centre/Chapel Allerton Hospital, Chapeltown Rd, Leeds, LS7 4SA, UK. P.Emery@leeds.ac.uk.
Tanaka Y; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Cardillo T; Eli Lilly and Company, Indianapolis, IN, USA.
Schlichting D; Eli Lilly and Company, Indianapolis, IN, USA.
Rooney T; Eli Lilly and Company, Indianapolis, IN, USA.
Beattie S; Eli Lilly and Company, Indianapolis, IN, USA.
Helt C; Eli Lilly and Company, Indianapolis, IN, USA.
Smolen JS; Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria.

Arthritis Res Ther ; 22(1): 166, 2020 07 02.

Article en En | MEDLINE | ID: mdl-32616069

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Arthritis Res Ther Asunto de la revista: REUMATOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google